

Applicants submit herewith a revised Sequence Listing in paper and computer-readable form. Please enter this revised Sequence Listing into the specification of the above-captioned application.


I hereby state that the content of the paper and computer readable copies of the revised Sequence Listing submitted in accordance with 37 C.F.R. §§ 1.821(c) and (e), respectively, are the same.

I hereby state that the content of the paper and computer readable copies of the revised Sequence Listing, submitted herewith in accordance with 37 C.F.R. § 1.82(f), does not include new matter.

Applicants request an early and favorable consideration of this application.

Applicants believe no fees are due with this Response. However, in the event that fees are due, the Commissioner is hereby authorized to charge payment of any additional fees associated with this communication to Deposit Account No. 02-4377. Two copies of this paper are enclosed.

Respectfully submitted,



Louis S. Sorell
Patent Office Reg. No. 32,439

Alicia A. Russo
Patent Office Reg. No. 46,192

Attorneys for Applicants

BAKER BOTTS, L.L.P.
30 Rockefeller Plaza
New York, NY 10112
(212) 408-2500

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

Please amend claim 1 to read as follows:

1. (Twice Amended) An isolated peptide comprising the peptide sequence of formula (I),

Xaa-Cys-Xab-Cys-Xac-Cys-Xad-Cys-Xae-Cys-Xaf-Cys-Xag (SEQ ID NO:39)

(I)

in which:

Xaa is $-NH_2$ or a peptide residue consisting essentially of from 1 to 10 amino acids; preferably from 1 to 6 amino acids;

Xab is a peptide residue consisting essentially of from 1 to 10 amino acids, preferably 10;

Xac is a peptide residue of 3 amino acids;

Xad is a peptide residue consisting essentially of from 1 to 9 amino acids, preferably 9;

Xae is a peptide residue consisting essentially of from 1 to 7 amino acids, preferably 7;

Xaf is a peptide residue of 1 amino acid; and

Xag is $-OH$ or a peptide residue consisting essentially of from 1 to 5 amino acids, preferably 1 or 2 amino acids.

5. (Amended) Peptide according to claim 1, characterized in that Xad represents the following peptide sequence $-Lys-Xad'-Xad''-Gly-His-$ (SEQ ID NO:40), in which Xad'

represents a peptide residue of 1 basic amino acid and Xad" represents a peptide residue comprising from 0 to 5 amino acids, preferably 5.

6. (Amended) Peptide according to claim 1, characterized in that Xad represents the following peptide sequence -Lys-Arg-Arg-Gly-Tyr-Lys-Gly-Gly-His- (SEQ ID NO:41).

11. (Amended) Peptide according to claim 1, characterized in that Xaa represents the following peptide sequence Xaa'-Gly-Xaa"- (SEQ ID NO:42), in which Xaa' represents NH₂ or a peptide residue comprising 1 to 9 amino acids, preferably 1 to 5 amino acids, and Xaa" represents a peptide residue comprising at least one amino acid, preferably chosen from Leu, Ile, Val, Pro, Ser or Thr, and/or

Xab represents the following peptide sequence -Val-Xab'-Asp- (SEQ ID NO:43) in which Xab' represents a peptide residue comprising from 0 to 8 amino acids, preferably 8, and/or

Xae represents the following peptide sequence -Gly-Xae'-Asn- (SEQ ID NO:44), in which Xae' represents a peptide residue comprising from 0 to 5 amino acids, preferably 5, and/or

Xaf represents one of the following amino acids Trp, Phe, Leu, Ile or Val, and/or

Xag represents the following peptide sequence -Glu-Xag' (SEQ ID NO:45), in which Xag' represents OH or a variable residue having a sequence comprising 1 to 4 amino acids, preferably 1 amino acid.

12. (Amended) Peptide according to claim 1, characterized in that Xaa represents the following peptide sequence NH₂-Asp-Lys-Leu-Ile-Gly-Ser- (SEQ ID NO:46), and/or

Xab represents the following peptide sequence -Val-Trp-Gly-Ala-Val-Asn-Tyr-Thr-Ser-Asp- (SEQ ID NO:47), and/or

Xae represents the following peptide sequence -Gly-Ser-Phe-Ala-Asn-Val-Asn (SEQ ID NO:48),
and/or

Xaf represents the following amino acid -Trp- and/or

Xag represents the following peptide sequence -Glu-Thr-OH.

16. (Amended) Peptide according to claim 1, characterized in that it comprises disulf[ph]ide bridges established between the first and fourth cysteine residues, the second and fifth cysteine residues, and the third and sixth cysteine residues of the peptide sequence of formula (I).